SurePath™ Imaging Pap and HPV DNA
Use
This combined test is used for cervical cancer screening by performing a SurePath liquid‑based Pap test in conjunction with high‑risk HPV DNA detection. It enables detection of cytologic abnormalities alongside HPV types associated with malignancy, facilitating co‑testing to improve sensitivity for precancerous and cancerous lesions.
Special Instructions
Not provided.
Limitations
Pap testing is a screening—not diagnostic—method and is subject to false negatives and positives. Accuracy depends on specimen adequacy and patient history. HPV detection is limited to high‑risk types and does not identify low‑risk or non‑HPV causes of cytologic changes.
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
5 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue
Volume
Not provided
Minimum Volume
1 SurePath™ pap vial
Container
SurePath™ pap vial
Collection Instructions
Pap sample collected in 1 SurePath™ pap vial; refer to specimen collection guide for details
Causes for Rejection
SurePath™ vials without the head of the collection device in the fluid; vials received frozen; swabs; vaginal specimens; cervical swabs in Digene® HC cervical sampler; Digene® vials
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 28 days |
| Refrigerated | 90 days |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant